Relmada Acquires Promising Tourette’s Syndrome Drug Candidate from Asarina Pharma
Relmada Therapeutics has acquired Sepranolone, a Phase 2b-ready neurosteroid, from Swedish biotech Asarina Pharma for €3 million ($3.1 million)14.
Sepranolone is being developed for Tourette's syndrome (TS) and other compulsion-related conditions14.
The acquisition comes after Relmada's previous setback in Phase 3 trials for a major depressive disorder drug38.
Sepranolone showed promising results in a Phase 2a study, reducing tic severity by 28% compared to 12.6% with standard care4.
The drug demonstrated a favorable safety profile with no systemic side effects in clinical trials involving over 335 subjects7.
Sepranolone is a GABAA Modulating Steroid Antagonist (GAMSA) that targets the GABAA pathway to counteract Allopregnanolone, a neurosteroid linked to TS1.
Relmada plans to advance Sepranolone into Phase 2b studies for Tourette's syndrome24.
The acquisition aligns with Relmada's mission to develop treatments for difficult-to-treat central nervous system (CNS) disorders19.
This move is part of Relmada's strategic efforts to maximize shareholder value following recent clinical setbacks89.
Asarina Pharma had previously announced plans to liquidate before successfully selling off its Tourette's syndrome candidate4.
Sources:
1. https://www.worldpharmaceuticals.net/news/relmada-acquires-tourette-syndrome-candidate-sepranolone-from-asarina-pharma/
2. https://storage.mfn.se/54d7214d-e5f3-4dd3-baa7-17b3e365c393/asarina-pharma-sells-sepranolone-assets-to-relmada-therapeutics.pdf
3. https://www.biopharmadive.com/news/relmada-depression-drug-study-results/634023/
4. https://www.fiercebiotech.com/biotech/after-ph-3-miss-relmada-picks-midstage-tourettes-asset-swedish-biotech
7. https://www.pharmaceutical-technology.com/news/relmada-ts-rights-asarina/
8. https://ftp.fiercelifesciences.com/biotech/relmada-halts-two-phase-3-trials-depression-drug-seeks-strategic-move-maximize-shareholder
9. https://www.relmada.com/for-investors/news/detail/308/relmada-therapeutics-acquires-potential-therapy-for